MicroRNA-506 participates in pancreatic cancer pathogenesis by targeting PIM3

Molecular Medicine Reports

Volumn 12, Issue 4, 2015, Pages 5121-5126

  Du, Jundong ^a   Zheng, Xi ^b   Cai, Shouwang ^c   Zhu, Ziman ^a   Tan, Jingwang ^a   Hu, Bin ^a   Huang, Zhiqiang ^c   Jiao, Huabo ^a,c  

^a Department of Hepatobiliary Surgery ^*  (China)

^b Division Three for Senior Officers First Affiliated Hospital to the General Hospital of the PLA   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Cell proliferation; MicroRNA; Pancreatic cancer; PIM3

Indexed keywords

ARGONAUTE 2 PROTEIN; MICRORNA; MICRORNA 124; MICRORNA 15A; MICRORNA 15B; MICRORNA 16; MICRORNA 195; MICRORNA 203; MICRORNA 322; MICRORNA 33A; MICRORNA 33B; MICRORNA 424; MICRORNA 497; MICRORNA 506; PIM3 PROTEIN; PROTEIN; RNA INDUCED SILENCING COMPLEX; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; MESSENGER RNA; MIRN506 MICRORNA, HUMAN; ONCOPROTEIN; PIM3 PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE;

3' UNTRANSLATED REGION; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; EXPRESSION VECTOR; GENE CONTROL; GENE EXPRESSION; GENE IDENTIFICATION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; LUCIFERASE ASSAY; MTT ASSAY; PANCREAS CANCER; PATHOGENESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; CELL LINE; CELL TRANSFORMATION; GENE EXPRESSION REGULATION; GENETICS; PANCREAS TUMOR; REPORTER GENE; RNA INTERFERENCE;

3' UNTRANSLATED REGIONS; CELL LINE; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HUMANS; MICRORNAS; PANCREATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RNA INTERFERENCE; RNA, MESSENGER;

EID: 84940475141     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.4109     Document Type: Article

References (24)

1. Li D, Xie K, Wolff R and Abbruzzese JL: Pancreatic cancer. Lancet 363: 1049-1057, 2004.
2. Guo X and Cui Z: Current diagnosis and treatment of pancreatic cancer in China. Pancreas 31: 13-22, 2005.
3. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
4. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
5. Tang S, Bonaroti J, Unlu S, et al: Sweating the small stuff: MicroRNAs and genetic changes define pancreatic cancer. Pancreas 42: 740-759, 2013.
6. van Kampen JG, Marijnissen-van Zanten MA, Simmer F, van der Graaf WT, Ligtenberg MJ and Nagtegaal ID: Epigenetic targeting in pancreatic cancer. Cancer Treat Rev 40: 656-664, 2014.
7. Wood LD and Hruban RH: Genomic landscapes of pancreatic neoplasia. J Pathol Transl Med 49: 13-22, 2015.
8. Wu WK, Lee CW, Cho CH, et al: MicroRNA dysregulation in gastric cancer: a new player enters the game. Oncogene 29: 5761-5771, 2010.
9. Nicoloso MS, Spizzo R, Shimizu M, Rossi S and Calin GA: MicroRNAs-the micro steering wheel of tumour metastases. Nat Rev Cancer 9: 293-302, 2009.
10. Ikenaga N, Ohuchida K, Mizumoto K, et al: MicroRNA-203 expression as a new prognostic marker of pancreatic adenocar-cinoma. Ann Surg Oncol 17: 3120-3128, 2010.
11. Izumchenko E, Chang X, Michailidi C, et al: The TGFβ-miR200-MIG6 pathway orchestrates the EMT-associated kinase switch that induces resistance to EGFR inhibitors. Cancer Res 74: 3995-4005, 2014.
12. Feldman JD, Vician L, Crispino M, et al: KID-1, a protein kinase induced by depolarization in brain. J Biol Chem 273: 16535-16543, 1998.
13. Konietzko U, Kauselmann G, Scafidi J, et al: Pim kinase expression is induced by LTP stimulation and required for the consolidation of enduring LTP. EMBO J 18: 3359-3369, 1999.
14. Li YY, Popivanova BK, Nagai Y, Ishikura H, Fujii C and Mukaida N: Pim-3, a proto-oncogene with serine/threonine kinase activity, is aberrantly expressed in human pancreatic cancer and phosphorylates bad to block bad-mediated apoptosis in human pancreatic cancer cell lines. Cancer Res 66: 6741-6747, 2006.
15. Li YY, Wu Y, Tsuneyama K, Baba T and Mukaida N: Essential contribution of Ets-1 to constitutive Pim-3 expression in human pancreatic cancer cells. Cancer Sci 100: 396-404, 2009.
16. Chang M, Kanwar N, Feng E, et al: PIM kinase inhibitors down-regulate STAT3 (Tyr705) phosphorylation. Mol Cancer Ther 9: 2478-2487, 2010.
17. Jass JR, Sobin LH and Watanabe H: The World Health Organization's histologic classifcation of gastrointestinal tumors. A commentary on the second edition. Cancer 66: 2162-2167, 1990.
18. Liu B, Wang Z, Li HY, Zhang B, Ping B and Li YY: Pim-3 promotes human pancreatic cancer growth by regulating tumor vasculogenesis. Oncol Rep 31: 2625-2634, 2014.
19. Yang FQ, Zhang HM, Chen SJ, Yan Y and Zheng JH: MiR-506 is down-regulated in clear cell renal cell carcinoma and inhibits cell growth and metastasis via targeting FLOT1. PloS One 10: e0120258, 2015.
20. Wen SY, Lin Y, Yu YQ, et al: miR-506 acts as a tumor suppressor by directly targeting the hedgehog pathway transcription factor Gli3 in human cervical cancer. Oncogene 34: 717-725, 2015.
21. Liu G, Sun Y, Ji P, et al: MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer. J Pathol 233: 308-318, 2014.
22. Arora H, Qureshi R and Park WY: miR-506 regulates epithelial mesenchymal transition in breast cancer cell lines. PLoS One 8: e64273, 2013.
23. Yin M, Ren X, Zhang X, et al: Selective killing of lung cancer cells by miRNA-506 molecule through inhibiting NF-κB p65 to evoke reactive oxygen species generation and p53 activation. Oncogene 34: 691-703, 2015.
24. Streicher KL, Zhu W, Lehmann KP, et al: A novel oncogenic role for the miRNA-506-514 cluster in initiating melanocyte transformation and promoting melanoma growth. Oncogene 31: 1558-1570, 2012.